Tolero doses first patient in Phase l trial of TP-1287 to treat tumours

admin

Tolero Pharmaceuticals has dosed the first patient in a Phase I trial assessing TP-1287 for the treatment of patients with advanced solid tumours.

Free Whitepaper

Expert proximity, integrated development, superior technologies

The softgel capsule has built a strong reputation in the prescription, consumer health and supplement market to become the preferred dosage form for consumers around the world. A format that has continuously reinvented itself, softgel technology delivers a number of benefits, including increased compliance and fewer doses, a longer shelf life, the enhanced bioavailabilty of active ingredients, and the masking of unpleasant odours and flavours. Here, Procaps examines the key characteristics and applications for softgel technology and how the latest advancements in the sector are keeping them at the forefront of the pharma industry.

By Procaps

By downloading this case study, you acknowledge that GlobalData may share your information with Procaps and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase l trial is currently taking place at sites in the US and intends to investigate the maximum tolerated dose and dose-limiting toxicities of TP-1287.

Tolero intends to enrol 60 patients as part of the open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamics trial.

Patients with advanced metastatic or progressive solid tumours who are refractory to, or intolerant of will be eligible for the trial.

“The initiation of this study is an important step forward in understanding the potential of TP-1287.”

The trial’s primary endpoints are to establish the maximum tolerated dose and dose-limiting toxicities of oral TP-1287, as well as determine the Recommended Phase II Dose (RP2D).

Secondary endpoints comprise pharmacokinetics, antitumour activity, and pharmacodynamics of TP-1287.

The study is set to be completed in May 2021 and primary data is expected to be available by February 2021.

Tolero Pharmaceuticals CEO David Bearss said: “The initiation of this study is an important step forward in understanding the potential of TP-1287 in patients with solid tumours.

“We believe that the oral administration of TP-1287 may be beneficial in disease settings where this form of administration is preferred or when used in combination with other targeted agents.”

TP-1287 is an experimental oral cyclin-dependent kinase 9 (CDK9) inhibitor that showed positive oral bioavailability in preclinical models.